A new DNA-based therapy could cut cholesterol nearly in half—without relying on statins or causing side effects.

Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine ...

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

Researchers have unveiled a new DNA-based therapy that silences the PCSK9 gene to lower cholesterol without statin side effects. Early results show dramatic reductions in cholesterol levels, offering ...

Scientists at the University of Barcelona have unveiled a DNA-based therapy that dramatically lowers cholesterol by targeting ...

When mice are engineered to carry a variant of the human PCSK9 gene, they experience higher rates of breast cancer metastasis, as is apparent in these images of mouse lung tissue showing PCSK9’s ...

A preclinical study presented at the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), held in ...

Verve Therapeutics Inc (NASDAQ:VERV) on Monday released initial data from the Heart-2 Phase 1b trial of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature ...

Scientists have developed a breakthrough therapy that could revolutionise the treatment of high cholesterol, which currently ...

The last time I wrote about Verve Therapeutics (VERV), it was in a Seeking Alpha article entitled "Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts." With ...

BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its ...